Regeneron Unveils Key Oncology Pipeline Updates at ESMO 2025, Highlighting Patient-Centric Approaches for Hard-to-Treat Cancers Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that new and updated data from its oncology pipeline will be presented in seven abstracts at the European…
Merck Presents New Phase 3 Data on Investigational Two-Drug HIV Regimen Doravirine/Islatravir (DOR/ISL) Showing Minimal Impact on Weight, Body Composition, and Lipid Levels Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, announced new results from its Phase…
Novo Nordisk Acquires Global Rights to Omeros’ MASP-3 Inhibitor Zaltenibart in $2.1 Billion Agreement Novo Nordisk and Omeros Corporation (Nasdaq: OMER) have entered into a definitive asset purchase and license agreement for zaltenibart (formerly OMS906), a clinical-stage antibody targeting MASP-3…
WHO Medical Product Alert N°5/2025: Identification of Substandard (Contaminated) Oral Liquid Medicines in the South-East Asia Region The World Health Organization (WHO) has issued Medical Product Alert N°5/2025 concerning the identification of substandard, contaminated oral liquid medicines in India, which…
WHO Launches EIOS 2.0 to Strengthen Global Health Intelligence and Threat Detection The World Health Organization (WHO) today announced the official launch of version 2.0 of its Epidemic Intelligence from Open Sources (EIOS) system, a major milestone in global health…
AbbVie to Present Comprehensive Data on Antibody-Drug Conjugate Portfolio at ESMO 2025, Reinforcing Leadership in Targeted Solid Tumor Therapies AbbVie (NYSE: ABBV) announced today that it will present a robust set of new clinical data from its antibody-drug conjugate (ADC)…
WuXi Biologics Applauds Sonoma Biotherapeutics Co-Founder Dr. Fred Ramsdell on Receiving the 2025 Nobel Prize in Physiology or Medicine WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), proudly congratulated Fred Ramsdell, PhD, co-founder and Chair…
Neurology Publication Demonstrates 95% Reduction in Mortality Risk with Pyrimidine Nucleos(t)ide Therapy in Patients with Thymidine Kinase 2 Deficiency (TK2d) UCB, a global biopharmaceutical company focused on the discovery and development of innovative treatments for serious diseases, today announced the…
BeOne Medicines’ Sonrotoclax Granted Breakthrough Therapy Designation by U.S. FDA, Set to Participate in Project Orbis BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology-focused biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA)…
LEQEMBI® IQLIK™ Subcutaneous Autoinjector Named One of TIME’s “Best Inventions of 2025” Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher) today announced that LEQEMBI® IQLIK™, a subcutaneous autoinjector…
Regeneron Presents Latest DB-OTO Data Showing Dramatic and Sustained Hearing and Speech Improvements in Children with Profound Genetic Hearing Loss Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced updated data for its investigational gene therapy DB-OTO for profound genetic hearing loss…
CVS Health® 2025 Rx Report Highlights the Evolution of Community Pharmacy to Meet Patient Needs CVS Health® (NYSE: CVS) today unveiled its 2025 Rx Report, Community Pharmacy Reimagined, offering a detailed exploration of how community pharmacies are evolving to meet…